Style | Citing Format |
---|---|
MLA | Golestannejad Z, et al.. "A Novel Drug Delivery System Using Acyclovir Nanofiber Patch for Topical Treatment of Recurrent Herpes Labialis: A Randomized Clinical Trial." Clinical and Experimental Dental Research, vol. 8, no. 1, 2022, pp. 184-190. |
APA | Golestannejad Z, Khozeimeh F, Mehrasa M, Mirzaeei S, Sarfaraz D (2022). A Novel Drug Delivery System Using Acyclovir Nanofiber Patch for Topical Treatment of Recurrent Herpes Labialis: A Randomized Clinical Trial. Clinical and Experimental Dental Research, 8(1), 184-190. |
Chicago | Golestannejad Z, Khozeimeh F, Mehrasa M, Mirzaeei S, Sarfaraz D. "A Novel Drug Delivery System Using Acyclovir Nanofiber Patch for Topical Treatment of Recurrent Herpes Labialis: A Randomized Clinical Trial." Clinical and Experimental Dental Research 8, no. 1 (2022): 184-190. |
Harvard | Golestannejad Z et al. (2022) 'A Novel Drug Delivery System Using Acyclovir Nanofiber Patch for Topical Treatment of Recurrent Herpes Labialis: A Randomized Clinical Trial', Clinical and Experimental Dental Research, 8(1), pp. 184-190. |
Vancouver | Golestannejad Z, Khozeimeh F, Mehrasa M, Mirzaeei S, Sarfaraz D. A Novel Drug Delivery System Using Acyclovir Nanofiber Patch for Topical Treatment of Recurrent Herpes Labialis: A Randomized Clinical Trial. Clinical and Experimental Dental Research. 2022;8(1):184-190. |
BibTex | @article{ author = {Golestannejad Z and Khozeimeh F and Mehrasa M and Mirzaeei S and Sarfaraz D}, title = {A Novel Drug Delivery System Using Acyclovir Nanofiber Patch for Topical Treatment of Recurrent Herpes Labialis: A Randomized Clinical Trial}, journal = {Clinical and Experimental Dental Research}, volume = {8}, number = {1}, pages = {184-190}, year = {2022} } |
RIS | TY - JOUR AU - Golestannejad Z AU - Khozeimeh F AU - Mehrasa M AU - Mirzaeei S AU - Sarfaraz D TI - A Novel Drug Delivery System Using Acyclovir Nanofiber Patch for Topical Treatment of Recurrent Herpes Labialis: A Randomized Clinical Trial JO - Clinical and Experimental Dental Research VL - 8 IS - 1 SP - 184 EP - 190 PY - 2022 ER - |